News by subject: TRI

Daewoong Therapeutics, a biopharmaceutical company based in South Korea, is pioneering the development of the world's first-in-class eyedrop formulation for the treatment of diabetic eye diseases....

Shuttle Pharmaceuticals Holdings, Inc. , a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced receipt of written responses to...

AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and...

Omixon Biocomputing Ltd. announced today the launch of NanoTYPE  MONOTM and MONO allTM - RUO, a single locus human leukocyte antigen (HLA) amplification kit compatible with Oxford Nanopore's MinION TM  platform NanoTYPE  MONO is designed to empower...

Ziptek LLC, a Sarasota-based company specializing in knotless tissue repair and attachment solution devices for surgeons, has returned from a successful equity offering presentation at the prestigious New York Venture Forum held at the Javits Center...

Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid...

TEPKINLY® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapyConditional marketing...

Zucara Therapeutics Inc., ("Zucara" or the "Company") a diabetes life sciences company developing the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in...

Kintara Therapeutics, Inc. ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor therapies, today announced the presentation of compelling patient case studies in a poster at the 2023 European...

On September 15, "Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery" successfully kicked off. This marks the first time in recent years that the Company has organized an event specifically focused on pharmaceutical R&D innovation. The...

ImageBloom, a leading provider of healthcare and clinical research marketing solutions, is thrilled to announce its strategic partnership with Clinitiative Health Research, a renowned leader in clinical research innovation....

Omixon Biocomputing Ltd. announced today the launch of NanoTYPE  MONOtm and MONO alltm - RUO, a single locus human leukocyte antigen (HLA) amplification kit compatible with Oxford Nanopore's MinION tm  platform NanoTYPE  MONO is designed to empower...

On September 15, "Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery" successfully kicked off. This marks the first time in recent years that the Company has organized an event specifically focused on pharmaceutical R&D innovation. The...

Pierre Fabre Laboratories and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets....

BioArctic AB's (publ) partner Eisai announced today that "LEQEMBI® Intravenous Infusion" (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to...

Vial, a global full-service CRO providing tech-forward clinical trial management services, announced its participation as a sponsor, exhibitor, and speaker at the 21st Precision in Clinical Trials Summit, taking place in San Diego, CA, on October...

On September 23, 2023, oncologists and experts from more than 60 clinical research centers across the country gathered in Guangzhou to participate in the YL201 Phase I/II Investigators Meeting hosted by Suzhou MediLink Therapeutics Co., Ltd. The...

TEL AVIV, Israel, Sept. 22, 2023 /PRNewswire/ ?Galmed Pharmaceuticals Ltd. ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that the Company received a letter from...

 If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. Positive Opinion Based on Pivotal Study SHP643-301, Evaluating the Safety Profile and Pharmacokinetics (PK) of...

Approval adds to the treatment options for the more than 35 million adults in the U.S. affected by chronic kidney disease (CKD)Jardiance® (empagliflozin) 10 mg tablets significantly reduced the risk of kidney disease progression and cardiovascular...

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Seagen Inc. today announced positive topline results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for PADCEV® (enfortumab vedotin-ejfv) in...

Lipogems announced today that there are now 140 peer reviewed publications supporting Lipogems' MicroFat with 5 years of follow up in orthopaedics. "Lipogems has sought out to help patients that have tried conservative options and other therapies...

Via Nova Therapeutics, Inc., a biotechnology company focused on discovering and developing therapeutics to treat viral infections with significant unmet medical need, today announced the clearance of its Investigational New Drug (IND) application...

In a groundbreaking study published in Nature, a collaborative team of researchers from Hospital for Special Surgery (HSS) and Weill Cornell Medicine have discovered a new stem cell uniquely present in the spine. Vertebral stem cells, distinct from...

Lipogems announced today that there are now 140 peer reviewed publications supporting Lipogems' MicroFat with 5 years of follow up in orthopaedics....

Scientists have known for decades that pregnancy requires a mother's body to adjust so that her immune system does not attack the growing fetus as if it were a hostile foreign invader. Yet despite learning a great deal more about the...

A study has revealed new details about a key population of immune system cells critical to successful vaccination against the pandemic virus, SARS-CoV-2....

A drug development partnership between Evecxia Therapeutics and Quotient Sciences has resulted in the successful delivery of a Phase 1 clinical testing program for Evecxia's drug candidate EVX-101, which is in development for major depressive...

BioMarin Pharmaceutical Inc. , a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that new data on VOXZOGO® (vosoritide) in children with achondroplasia will be presented at the 61st Annual...

Transcend Therapeutics, a biotechnology company developing rapid-acting treatments for neuropsychiatric diseases, announced receipt of a collaborative grant award with Yale University to support first-of-its-kind preclinical research on methylone ?...

Journal of Oral Implantology ? Dental implant procedures can be challenging no matter the placement location in the mouth; however, implants in the back of the mouth?premolar and molars?can be especially...

Neurocrine Biosciences, Inc. , today announced that it will present a new post hoc analysis of Phase 2 data of the investigational drug crinecerfont in adolescent patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase...

Gilgamesh Pharma, a cutting-edge clinical-stage biotechnology company proudly announces the successful completion of its Phase 1 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) trials for GM-1020, the only novel oral, small-molecule...

Moleculin Biotech, Inc., (Moleculin or the Company), a clinical...

Cessatech A/S ("Cessatech" or "the Company") announces that the last participant has been...

PhenomeX Inc. , a functional cell biology company, is pleased to announce that GSK will present data on the SpotLighttm Human Lambda reagent for the Beacon® platform at the 16th annual Conference on Protein Expression in Animal Cells, which is being...

Lipella Pharmaceuticals Inc. ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the results of its successful Phase 2a clinical trial have...

AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced the publication of a case report and literature review by distribution partners commercially deploying AIVITA's Vaccine Kit, describing...

Endo International plc announced today that data from clinical studies of collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis will be presented during the American Orthopaedic Foot & Ankle Society's (AOFAS) annual...

Veeva Systems today announced that palleos healthcare has selected Veeva Vault Clinical Data Management Suite (CDMS) with Veeva Vault EDC and Veeva CDB (clinical database) to connect all clinical study data on one platform. A unified view of...

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, announced today the appointment of Samuel Barone, M.D., an accomplished leader in the pharmaceutical space and former FDA...

MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces the presentation of 6 Clinical Posters, a Presentation, and a Hands-On Workshop at the American...

The first results from an ongoing independent clinical study at the University of Kent, UK, show that ColdZyme® significantly reduces the viral load of rhinovirus, the predominant cause of the common cold. Additionally, participants who used ColdZyme...

Antengene...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases of the treatment of metastatic...

Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company's proprietary Lateral CAR platform,...

MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces the presentation of 6 Clinical Posters, a Presentation, and a Hands-On Workshop at the American...

A recent study evaluating the use of non-infused biologics in patients diagnosed with rheumatoid arthritis (RA) demonstrated that patients who are adherent to their non-infused RA biologic medication are more likely to have lower medical costs, odds...

A collaborative scientific team led by researchers at the Applied Biomedical Science Institute (ABS), Scripps Research, Kansas State University (K-State), University of Louisville, OmniAb, Inc., and Ligand Pharmaceuticals has discovered and validated...

Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients in Europe die annually from the disease²ORSERDU is the first...